Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia - Concepedia

Concepedia

Publication | Open Access

Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

DOI Full Paper Access

248

Citations

25

References

2005

Year

Eric J. Feldman, Joseph Brandwein, Richard M. Stone, Matt Kalaycio, Joseph O. Moore, Julie O’Connor, Nancy Wedel, Gail J. Roboz, Carole B. Miller, Raj Chopra,

Journal of Clinical Oncology

Abstract

The addition of lintuzumab to salvage induction chemotherapy was safe, but did not result in a statistically significant improvement in response rate or survival in patients with refractory/relapsed AML.

References

	Year	Citations

Page 1